Acciones Iqvia Holdings Inc Nyse
Acciones
US74876Y1010
Biotecnología e investigación médica
Ventas 2024 * | 15,49 mil M 14,26 mil M | Ventas 2025 * | 16,58 mil M 15,27 mil M | Capitalización | 42,82 mil M 39,44 mil M |
---|---|---|---|---|---|
Resultado Neto 2024 * | 1336 M 1230,54 M | Resultado Neto 2025 * | 1580 M 1455,28 M | VE / Ventas 2024 * | 3,53 x |
Deuda neta 2024 * | 11,83 mil M 10,89 mil M | Deuda neta 2025 * | 11,7 mil M 10,77 mil M | VE / Ventas 2025 * | 3,29 x |
P/E ratio 2024 * |
32
x | P/E ratio 2025 * |
26,8
x | Empleados | - |
Rendimiento 2024 * |
-
| Rendimiento 2025 * |
-
| Flotante | 69,84 % |
Último transcript sobre Iqvia Holdings Inc
Directores | Puesto | Edad | Desde |
---|---|---|---|
Ari Bousbib
CEO | Chief Executive Officer | 63 | 03/10/16 |
Ronald Bruehlman
DFI | Director of Finance/CFO | 63 | 01/08/20 |
James Berkshire
COO | Chief Operating Officer | 51 | 01/07/17 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
John Danhakl
BRD | Director/Board Member | 67 | 03/10/16 |
Colleen Goggins
BRD | Director/Board Member | 68 | 27/07/17 |
Ari Bousbib
CEO | Chief Executive Officer | 63 | 03/10/16 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+33,37 % | 49,46 mil M | |
+49,11 % | 42,49 mil M | |
-4,22 % | 29,09 mil M | |
+11,57 % | 26,61 mil M | |
-21,00 % | 18,64 mil M | |
+7,36 % | 13,16 mil M | |
+28,30 % | 12,55 mil M | |
+23,80 % | 12,1 mil M | |
-4,93 % | 11,98 mil M |